Trial: 202012040

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Phase

I/II

Principal Investigator

Vij, Ravi

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov